Acrux Limited (ARUXF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 9.7 Million AUD | -89.93% |
| 2023 | 11.26 Million AUD | -23.32% |
| 2022 | 14.68 Million AUD | -16.51% |
| 2021 | 17.58 Million AUD | 31.94% |
| 2020 | 13.33 Million AUD | -2.14% |
| 2019 | 13.62 Million AUD | -0.34% |
| 2018 | 13.66 Million AUD | 7.16% |
| 2017 | 12.75 Million AUD | 46.52% |
| 2016 | 8.7 Million AUD | 13.01% |
| 2015 | 7.7 Million AUD | 11.06% |
| 2014 | 6.93 Million AUD | 13.97% |
| 2013 | 6.08 Million AUD | 10.09% |
| 2012 | 5.52 Million AUD | -12.13% |
| 2011 | 6.29 Million AUD | 14.55% |
| 2010 | 5.49 Million AUD | -51.07% |
| 2009 | 11.22 Million AUD | -1.52% |
| 2008 | 11.39 Million AUD | -10.56% |
| 2007 | 12.74 Million AUD | -0.53% |
| 2006 | 12.81 Million AUD | 18.49% |
| 2005 | 10.81 Million AUD | 36.09% |
| 2004 | 7.94 Million AUD | 18.28% |
| 2003 | 6.71 Million AUD | 53.19% |
| 2002 | 4.38 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 3.9 Million AUD | -65.34% |
| 2024 Q2 | 1.95 Million AUD | -25.85% |
| 2024 Q4 | 2.13 Million AUD | 9.17% |
| 2023 Q4 | 2.63 Million AUD | -8.73% |
| 2023 Q2 | 2.88 Million AUD | -58.5% |
| 2023 FY | 11.26 Million AUD | -23.32% |
| 2022 FY | 14.68 Million AUD | -16.51% |
| 2022 Q4 | 6.95 Million AUD | -1.63% |
| 2022 Q2 | 7.07 Million AUD | -17.1% |
| 2021 Q4 | 8.52 Million AUD | 1.58% |
| 2021 FY | 17.58 Million AUD | 31.94% |
| 2021 Q2 | 8.39 Million AUD | 29.15% |
| 2020 FY | 13.33 Million AUD | -2.14% |
| 2020 Q4 | 6.5 Million AUD | 6.17% |
| 2020 Q2 | 6.12 Million AUD | -15.43% |
| 2019 FY | 13.62 Million AUD | -0.34% |
| 2019 Q2 | 4.24 Million AUD | -16.68% |
| 2019 Q4 | 7.23 Million AUD | 70.69% |
| 2018 Q2 | 11.11 Million AUD | -31.34% |
| 2018 Q4 | 5.09 Million AUD | -54.22% |
| 2018 FY | 13.66 Million AUD | 7.16% |
| 2017 FY | 12.75 Million AUD | 46.52% |
| 2017 Q4 | 16.19 Million AUD | 263.28% |
| 2017 Q2 | 4.45 Million AUD | 1.87% |
| 2016 Q4 | 4.37 Million AUD | 19.2% |
| 2016 FY | 8.7 Million AUD | 13.01% |
| 2016 Q2 | 3.67 Million AUD | -6.9% |
| 2015 FY | 7.7 Million AUD | 11.06% |
| 2015 Q4 | 3.94 Million AUD | 29.07% |
| 2015 Q2 | 3.05 Million AUD | -22.13% |
| 2014 Q4 | 3.92 Million AUD | 12.21% |
| 2014 FY | 6.93 Million AUD | 13.97% |
| 2014 Q2 | 3.49 Million AUD | 35.56% |
| 2013 Q4 | 2.57 Million AUD | -1.68% |
| 2013 Q2 | 2.62 Million AUD | 0.0% |
| 2013 FY | 6.08 Million AUD | 10.09% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 FY | 5.52 Million AUD | -12.13% |
| 2011 FY | 6.29 Million AUD | 14.55% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | 5.49 Million AUD | -51.07% |
| 2009 FY | 11.22 Million AUD | -1.52% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | 11.39 Million AUD | -10.56% |
| 2007 FY | 12.74 Million AUD | -0.53% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | 12.81 Million AUD | 18.49% |
| 2005 FY | 10.81 Million AUD | 36.09% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 FY | 7.94 Million AUD | 18.28% |
| 2003 FY | 6.71 Million AUD | 53.19% |
| 2002 FY | 4.38 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | 10.656% |
| Skye Bioscience, Inc. | 13.54 Million USD | 28.334% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 73.94% |
| Nascent Biotech, Inc. | 2.22 Million USD | -335.405% |
| Qrons Inc. | 643.67 Thousand USD | -1408.365% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 57.741% |
| CSL Limited | 3.44 Billion USD | 99.718% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 67.147% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -92.561% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -951.315% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 83.097% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2236.821% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1362.199% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -627.031% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2392.261% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 39.358% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 88.813% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -97.421% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3609.605% |
| SQZ Biotechnologies Company | 85.61 Million USD | 88.66% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -232.929% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -546.448% |
| Mesoblast Limited | 5.9 Million USD | -64.504% |
| Marizyme, Inc. | 19.23 Million USD | 49.537% |
| Genus plc | 147.7 Million USD | 93.427% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -10.591% |
| Pharming Group N.V. | 225.49 Million USD | 95.694% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -373.909% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -623.718% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -16.429% |
| ContraFect Corporation | 56.88 Million USD | 82.933% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -120.225% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -556.567% |
| IMV Inc. | 37.7 Million USD | 74.253% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -247.948% |
| MultiCell Technologies, Inc. | 567.42 USD | -1710978.214% |
| ONE Bio Corp. | 6.44 Million USD | -50.67% |
| Accustem Sciences Inc. | 3.74 Million USD | -159.154% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 88.703% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1725.13% |
| Q BioMed Inc. | 3.43 Million USD | -182.515% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 60.716% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -269.512% |
| Biomind Labs Inc. | 994.18 Thousand USD | -876.582% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 90.226% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -451.749% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -44.522% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -420.766% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 38936.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -429.073% |
| GB Sciences, Inc. | 1.42 Million USD | -583.487% |
| Alpha Cognition Inc. | 9.7 Million USD | -0.035% |
| HST Global, Inc. | 140.9 Thousand USD | -6790.36% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -763.091% |
| Halberd Corporation | 74.84 Thousand USD | -12872.662% |
| Enzolytics Inc. | 2.17 Million USD | -345.468% |
| Agentix Corp. | 1.37 Million USD | -607.779% |
| Resverlogix Corp. | 12.71 Million USD | 23.623% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -165.948% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.367% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -829.981% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -303.712% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -514.745% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -185.141% |
| AVAX Technologies, Inc. | 7.31 Million USD | -32.813% |
| Zenith Capital Corp. | 8.94 Million USD | -8.565% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.824% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -55631.588% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -295.428% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -5560.927% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -405.439% |
| Kadimastem Ltd | 2.41 Million USD | -302.844% |
| Helix BioMedix, Inc. | 1.97 Million USD | -392.334% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -5249.753% |
| LadRx Corporation | 3.81 Million USD | -154.71% |
| Cell Source, Inc. | 4.32 Million USD | -124.468% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -951.315% |
| NovAccess Global Inc. | 2.46 Million USD | -293.593% |
| Affymax, Inc. | 39.38 Million USD | 75.349% |
| Itoco Inc. | 919.14 Thousand USD | -956.31% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -129.072% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -767.65% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1650.802% |
| CytoDyn Inc. | 18.05 Million USD | 46.234% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -38475.231% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -4311.618% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -583.833% |
| SYBLEU INC | 160.87 Thousand USD | -5935.083% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -434.542% |
| International Stem Cell Corporation | 5.27 Million USD | -84.197% |
| Bioxytran, Inc. | 3.82 Million USD | -154.153% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -18343.448% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -47626.491% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 73.228% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -500.062% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1219.453% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -212.086% |
| Neutra Corp. | 243.82 Thousand USD | -3882.02% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 44.383% |
| PureTech Health plc | 144.59 Million USD | 93.285% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 52.616% |
| IXICO plc | 4.7 Million USD | -106.267% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -10.367% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 91.754% |
| CSL Limited | 3.89 Billion USD | 99.751% |
| Cellectis S.A. | 97.32 Million USD | 90.024% |